Danielle Hammond, MD
@daniellehammo20
Leukemia doc at MD Anderson πΊπΈ focusing on MDS-CH-VEXAS. Ex-pat π¨π¦. Believe in the transformative power of compassion and science. Love puns! Views my own.
ID: 4246291953
22-11-2015 02:03:14
4,4K Tweet
2,2K Followers
1,1K Following
Honoured to review updates in MDS and AML. Menin mania, long-term outcomes with 1L luspatercept, imetelstat, and so much more! MD Anderson Cancer Center #MDSsm #AMLsm
OCE Publication: Advancing Drug Development in Myelodysplastic Syndromes - collaboration between FDA, NCI, academia, and other stakeholders following our public workshop on advancing drug development in MDS. Blood Advances ashpublications.org/bloodadvances/β¦
Plasma Olink Proteomics study of large vessel vasculitis spectrum revealed β’Highly similar proteomic signatures in Takayasu & GCA β’β Innate immune activation, and β stromal remodeling Results have implications for biomarker and drug design In A&R doi.org/10.1002/art.43β¦
More on immune dysfunction in myeloid malignances simona colla shares ππΌ data on irreversible dysfunction of clonal NK cells in MDS (early as CCUS), in part due to π« NK synapse formation w/ loss of TET2 & DNMT3A #i4MDS MD Anderson Cancer Center Valeria Santini Shahram Kordasti #mdssm
CONGRESS | #Tandem25 | PRESENTATION Uday Popat, MD Anderson Cancer Center, presents results from a phase II trial evaluating myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa and venetoclax (Cladillac) conditioning regimen for allo-HSCT in 49 patients with very
Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. MD Anderson Cancer Center #Leukemia ASH ashpublications.org/bloodadvances/β¦
πππMD Education MPN, CHIP/CCUS & MDS faculty all coming together to discuss new ideas ! #MPNSM #leusm ||| π π‘ Ruben A. Mesa, MD Naveen Pemmaraju, MD | Heme Reports MPNCo&D Congress Aditi Pemmaraju, J.D. Sanam Loghavi, MD Ψ΅ΩΩ ΩΨΊΩΫ π¬π§¬ Hannah Goulart Zhuoer (Zoey) Xie, MD, MSCR Yazan Madanat, MD Mike Fradley, MD Elf Lab πΊπ¦π³οΈβππ³οΈββ§οΈβ§οΈππΎππ½ππ§
Great post by David Steensma, MD highlighting the difficulties of treating neoplastic conditions. When a trial is βnegativeβ itβs not the fault of the drug, the trial design, the investigators, or patients. Some cancers and pre cancers are just inherently hard to tackle:
βWeβre starting to see that patients treated with luspatercept have significantly longer survival compared to those treated with epoetin alfa,β G Garcia-Manero said. Bristol Myers Squibb sohoinsider.com/meetings-confeβ¦
πππDelighted to share our groupβs new paper π£ Nature Genetics led by .Koichi Takahashi and team MD Anderson Cancer Center π π π #leusm #endcancer | Naval Daver, M.D. Naveen Pemmaraju, MD Nitin Jain Robert Z. Orlowski Muzaffar Qazilbash Rashmi Kanagal-Shamanna, MD Dr. Elizabeth Shpall Peggy Goodell || nature.com/articles/s4158β¦ ||
πππDelighted to share our new collaborative article in Leukemia Journal led by π¨ Mrinal Patnaik & Guillermo Montalban-Bravo & Eric Padron MD | Sanam Loghavi, MD Ψ΅ΩΩ ΩΨΊΩΫ π¬π§¬ Rashmi Kanagal-Shamanna, MD Naveen Pemmaraju, MD Rami komrokji Naseema Gangat nature.com/articles/s4137β¦ | #leusm #TET2
Primary impact of clonal hematopoiesis on the outcomes of BCMA CAR-T in MM: prolonged transfusion-dependent cytopenias #mmsm #bmtsm Noopur Raje Blood Journals Portfolio ashpublications.org/bloodadvances/β¦
πClonal evolution of hematopoietic stem cells after autologous stem cell transplantation | β¦Nature Geneticsβ© .β¦Koichi Takahashiβ© #leusm #endcancer nature.com/articles/s4158β¦